StockData
Cognition Therapeutics Inc logo

Cognition Therapeutics Inc (CGTX) stock

CGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.64−0.04 (-6.03%)

Close on Nov 16, 2026Market cap $60.75MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$60.75M
P/E ratio
–
Price to sales
–
Price to book
1.84
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$16.78M
EPS, diluted
-$0.19
Book value per share
$0.36
Diluted shares
91M

Trading

Next earnings
Mar 25, 2027 (estimated, before the open)
Previous close
$0.68
Open
$0.69
Day's range
$0.61 – $0.69
Volume
503,676
Average volume (20 days)
416,964
52-week range
$0.55 – $1.81
RSI (14 days)
32.8
Volatility (1 year)
95.8%
Relative volume
0.93×

Market cap history

Month-end market cap since 2021, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.

PeriodCGTXS&P 500DifferenceCGTX per yearS&P 500 per year
1 month-12.5%-3.1%−9.4 pts
3 months-36.8%-4.5%−32.3 pts
Year to date-52.7%+9.4%−62.0 pts
1 year-58.8%+11.3%−70.1 pts
3 years-36.1%+70.4%−106.5 pts-13.9%+19.4%
5 years-93.9%+68.6%−162.5 pts-42.9%+11.0%

Seven years at a glance

Fiscal years 2019 to 2025 and trailing twelve months, USD

Operating income

-$36.60M

Net income

-$16.78M

EPS, diluted

-$0.19

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Cognition Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Cognition Therapeutics

Biological Products, (No Diagnostic Substances)

Cognition is a clinical-stage biopharmaceutical company that discovers and develops small molecule drug candidates for age-related degenerative disorders of the central nervous system and retina. The company focuses on developing disease-modifying therapies designed to protect neuronal synapses from toxic protein oligomers. Its primary pipeline candidate is zervimesine, also identified as CT1812, an orally administered therapeutic being evaluated for Alzheimer’s disease and dementia with Lewy bodies. Its target recipients are patients experiencing cognitive decline, mild cognitive impairment, and associated neurodegenerative conditions.

Company profile, executives and history

Cognition Therapeutics stock: common questions

What is Cognition Therapeutics's stock price?

CGTX closed at $0.64 on Nov 16, 2026, down 6.03% on the day. Over the past 52 weeks it traded between $0.55 and $1.81.

What is Cognition Therapeutics's market cap?

Cognition Therapeutics was worth $60.75M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.

What is CGTX's P/E ratio?

Cognition Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.19), so it has no meaningful P/E ratio.

Does Cognition Therapeutics pay a dividend?

No. Cognition Therapeutics has not paid a cash dividend over the last twelve months.

When does Cognition Therapeutics report earnings next?

Cognition Therapeutics is expected to report Q4 FY2026 results on Mar 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.

How has CGTX stock performed over the past year?

Including dividends, CGTX returned -58.8% over the past year, against +11.3% for the S&P 500.

How many CGTX shares are sold short?

7M shares were sold short at the latest FINRA report, 8.11% of the float, or 15.3 days of average trading volume.

Who are Cognition Therapeutics's competitors?

Companies most similar to Cognition Therapeutics by business, industry and size include ABOS, ALEC, NMRA, PASG, AVXL.

See a number that looks wrong?